Disease block
C64-C68 – Bösartige Neubildungen der Harnorgane
- Chapter II: Neubildungen
35Decisions
56Patient groups
Added benefit by patient group
- Considerable14
- Minor6
- Non-quantifiable2
- Not proven34
Diseases in this disease block
- C64 Bösartige Neubildung der Niere, ausgenommen Nierenbecken 21 decisions
- C65 Bösartige Neubildung des Nierenbeckens 18 decisions
- C66 Bösartige Neubildung des Ureters 18 decisions
- C67 Bösartige Neubildung der Harnblase 19 decisions
- C68 Bösartige Neubildung sonstiger und nicht näher bezeichneter Harnorgane 18 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-06-04OpdivoNivolumabConsiderable
- 2026-01-22ImfinziDurvalumabMinor
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-09-18WeliregBelzutifanMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-06-18BalversaErdafitinibNot proven: 3 of 3 patient groups
- 2025-04-03PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2025-04-03KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNon-quantifiable: 1 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2024-12-19OpdivoNivolumabNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-01-19KeytrudaPembrolizumabMinor
- 2022-12-01PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-10-20OpdivoNivolumabNot proven
- 2022-07-07KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2022-07-07KisplyxLenvatinibNot proven: 2 of 2 patient groups
- 2021-10-21OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2021-10-21Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2021-09-16KeytrudaPembrolizumabNot proven
- 2021-08-19BavencioAvelumabConsiderable
- 2021-07-01KisplyxLenvatinibNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-05-14KeytrudaPembrolizumabConsiderable: 2 of 2 patient groups
- 2020-05-14BavencioAvelumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-04-02VitrakviLarotrectinibNot proven
- 2019-08-15YervoyIpilimumabConsiderable: 2 of 2 patient groups
- 2019-08-15OpdivoNivolumabConsiderable: 2 of 2 patient groups
- 2019-06-20TecentriqAtezolizumabNot proven
- 2018-12-06Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2018-04-19FotivdaTivozanibNot proven: 3 of 3 patient groups
- 2018-04-05Cabometyx CabozantinibMinor
- 2018-03-16TecentriqAtezolizumabMinor
- 2018-03-16KeytrudaPembrolizumabConsiderable
- 2017-12-21OpdivoNivolumabNot proven
- 2017-09-21InlytaAxitinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
Data status: 2026-10-29